MedTrace Logo

Corticosteroid Nasal Spray in COVID-19 Anosmia

NCT04484493 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-11-13

No results posted yet for this study

Summary

The aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19 infection.

Conditions

  • Covid19
  • Anosmia

Interventions

DRUG

mometasone furoate nasal spray

dose of 2 puff in each nostril (100 µg once daily each nostril).

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Abdelrahman A Abdelalim, MD · Benha University

  • Rasha A Elsayed, MD · Benha University

  • Mona A Elawady, MD · Benha University

  • Abdelhakim F Ghallab, MD · Benha University

  • Ayman A Mohamady, MD · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-08
Primary Completion
2020-10-25
Completion
2020-11-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04484493 on ClinicalTrials.gov